These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Gibril F; Reynolds JC; Doppman JL; Chen CC; Venzon DJ; Termanini B; Weber HC; Stewart CA; Jensen RT Ann Intern Med; 1996 Jul; 125(1):26-34. PubMed ID: 8644985 [TBL] [Abstract][Full Text] [Related]
4. Definition of the role of somatostatin receptor scintigraphy in gastrointestinal neuroendocrine tumor localization. Jensen RT; Gibril F; Termanini B Yale J Biol Med; 1997; 70(5-6):481-500. PubMed ID: 9825476 [TBL] [Abstract][Full Text] [Related]
5. [The scintigraphy of somatostatin receptors in the carcinoid tumor]. Banzo J; Abós MD; Prats E; Delgado M; Razola P; García S; Gomollón F; García F Rev Esp Med Nucl; 2001 Feb; 20(1):11-8. PubMed ID: 11181324 [TBL] [Abstract][Full Text] [Related]
6. [Somatostatin receptor scintigraphy in neuroendocrine tumors exemplified by a patient with hepatic metastases of gastrinoma]. Behr T; Becker W; Koch W; Grebmeier J; Wolf F Z Gastroenterol; 1994 Feb; 32(2):100-4. PubMed ID: 7513113 [TBL] [Abstract][Full Text] [Related]
7. Detection of multiple hepatic metastases of gastrinoma not apparent on CT by In-111 octerotide scintigraphy. McInerney GF; Carmalt H; MaGee M; Allman K; van der Wall H Clin Nucl Med; 1996 Sep; 21(9):730-1. PubMed ID: 8879876 [No Abstract] [Full Text] [Related]
10. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors. Krausz Y; Bar-Ziv J; de Jong RB; Ish-Shalom S; Chisin R; Shibley N; Glaser B Am J Gastroenterol; 1998 Jan; 93(1):66-70. PubMed ID: 9448177 [TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide and somatostatin receptor scintigraphy for differential diagnosis of hepatic carcinoid metastasis. Kurtaran A; Raderer M; Müller C; Prokesch R; Kaserer K; Eibenberger K; Koperna K; Niederle B; Virgolini I J Nucl Med; 1997 Jun; 38(6):880-1. PubMed ID: 9189133 [TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor scintigraphy of malignant somatostatinoma with indium-111-pentetreotide. Schillaci O; Annibale B; Scopinaro F; delle Fave G; Colella AC J Nucl Med; 1997 Jun; 38(6):886-7. PubMed ID: 9189135 [TBL] [Abstract][Full Text] [Related]
13. Single-pass CT of hepatic tumors: value of globular enhancement in distinguishing hemangiomas from hypervascular metastases. Leslie DF; Johnson CD; MacCarty RL; Ward EM; Ilstrup DM; Harmsen WS AJR Am J Roentgenol; 1995 Dec; 165(6):1403-6. PubMed ID: 7484574 [TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. GRESZE: Groupe d'Etude du Syndrome de Zollinger-Ellison. de Kerviler E; Cadiot G; Lebtahi R; Faraggi M; Le Guludec D; Mignon M Eur J Nucl Med; 1994 Nov; 21(11):1191-7. PubMed ID: 7859770 [TBL] [Abstract][Full Text] [Related]
15. The value of somatostatin-receptor scintigraphy in newly diagnosed endocrine gastroenteropancreatic tumors. Kisker O; Bartsch D; Weinel RJ; Joseph K; Welcke UH; Zaraca F; Rothmund M J Am Coll Surg; 1997 May; 184(5):487-92. PubMed ID: 9145069 [TBL] [Abstract][Full Text] [Related]
16. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy. Lebtahi R; Cadiot G; Delahaye N; Genin R; Daou D; Peker MC; Chosidow D; Faraggi M; Mignon M; Le Guludec D J Nucl Med; 1999 Oct; 40(10):1602-8. PubMed ID: 10520698 [TBL] [Abstract][Full Text] [Related]
17. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management. Gibril F; Doppman JL; Reynolds JC; Chen CC; Sutliff VE; Yu F; Serrano J; Venzon DJ; Jensen RT J Clin Oncol; 1998 Mar; 16(3):1040-53. PubMed ID: 9508189 [TBL] [Abstract][Full Text] [Related]
18. Octreotide scintigraphy: a prerequisite for liver transplantation for metastatic gastrinoma. Chui AK; Jayasundera MV; Haghighi KS; Rao AR; Koorey D; McCaughan GW; Rajaratnam SK; Eberl S; Bautovich G; Sheil AG Aust N Z J Surg; 1998 Jun; 68(6):458-60. PubMed ID: 9623469 [No Abstract] [Full Text] [Related]
19. [A case of metastatic gastrinomas in the liver visualized by 111In-DTPA-D-Phe-octreotide (111In-pentetreotide)]. Tani A; Nakabeppu Y; Tsuchimochi S; Nakajo M; Yoshinaga T; Kiku T Kaku Igaku; 1996 May; 33(5):545-9. PubMed ID: 8699623 [TBL] [Abstract][Full Text] [Related]
20. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. Baudin E; Lumbroso J; Schlumberger M; Leclere J; Giammarile F; Gardet P; Roche A; Travagli JP; Parmentier C J Nucl Med; 1996 Jun; 37(6):912-6. PubMed ID: 8683310 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]